Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy

European Journal of Medical Research

Guillermo Giménez-Gallego¹  Javier Angulo³  Carlos Azanza²  Luis A Outeiriño²  Pedro Cuevas³ 

[1]Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, CSIC. C/ Ramiro de Maeztu 9, Madrid -28040, Spain

[2]Departamento de Oftalmología, Hospital de Día Pío XII, Cuesta Sagrados Corazones 4, Madrid -28016, Spain

[3]Departamento de Investigación, IRYCIS, Hospital Universitario Ramón y Cajal, Ctra. de Colmenar, km. 9.100, Madrid -28034, Spain

关键词: Intravitreal injection;    Dobesilate;    Fibroblast growth factor;    Central serous chorioretinopathy;   

Others  :  820244
DOI  :  10.1186/2047-783X-17-22

 received in 2012-03-28, accepted in 2012-07-02,  发布年份 2012

【 摘 要 】

Purpose

To report the anatomic and functional outcome of intravitreal dobesilate to treat recurrent central serous chorioretinopathy (CSC).

Methods

This is an interventional case report in which dobesilate was intravitreally injected in a case of recurrent CSC. Main measures included fundoscopy, Snellen visual acuity (VA) testing, fluorescein angiography and optical coherence tomography (OCT).

Results

We present anatomical and functional evidences, obtained as early as eleven days after the treatment, of the efficacy of intravitreal dobesilate, in the treatment of chronic CSC condition. The effect after intravitreal dobesilate injection for CSC might be related to the normalization of retinal architecture.

Conclusions

Intravitreal dobesilate may be an effective treatment option for recurrent CSC.

【 授权许可】

   
2012 Cuevas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Klein ML, Van Buskirk EM, Friedman E, Gragoudas E, Chandra S: Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol 1974, 91:247-250.
• [2]Lafaut BA, Salati C, Priem H, De Laey JJ: Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patients. Graefes Arch Clin Exp Ophthalmol 1998, 236:513-521.
• [3]Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo A, Lozano RM, Valverde S, Jiménez-Barbero J, Romero A, Giménez-Gallego G: Gentisic acid, a compound associated with plant defence and a metabolite of aspirin, heads a new class of in vivo FGF inhibitor. J Biol Chem 2010, 285:1714-1729.
• [4]Angulo J, Peiró C, Romacho T, Fernández A, Cuevas B, González-Corrochano R, Giménez-Gallego G, Sáenz de Tejada I, Sánchez-Ferrer CF, Cuevas P: Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011, 667:153-159.
• [5]Spide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996, 103:2070-80.
• [6]Loo RH, Scott IU, Flynn HW, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE: Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002, 22:19-24.
• [7]Iida T, Hagimura N, Sato T, Kishi S: Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol 2000, 129:16-20.
• [8]Gomolin JE: Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol 1989, 24:20-23.
• [9]Nowilaty SR, Bouhaimed M: Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Photodynamic Therapy Study Group. Br J Ophthalmol 2006, 90:982-986.
• [10]Gass JD, Sever RJ, Sparks D, Goren J: A combined technique of fluorescein funduscopy and angiography of the eye. Arch Ophthalmol 1967, 78:455-461.
• [11]Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL: Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 1984, 91:1544-1548.
• [12]Hussain D, Gass JD: Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998, 46:131-137.
• [13]Wang M, Munch IC, Hasler PW, Prünte C, Larsen M: Central serous chorioretinopathy. Acta Ophthalmol 2008, 86:126-145.
• [14]Gemenetzi M, De Salvo G, Lotery AJ: Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010, 24:1743-1756.
• [15]Watzke RC, Burton TC, Leaverton P: Ruby laser photocoagulation therapy of central serous retinopathy. A preliminary report. Mod Probl Ophthalmol 1974, 12:242-246.
• [16]Burumcek E, Mudun A, Karacorlu S, Arslan MO: Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997, 104:616-622.
• [17]Robertson DM, Ilstrup D: Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983, 95:457-466.
• [18]Gärtner J: Long-term follow-up of an ophthalmologist's central serous retinopathy, photocoagulated by sungazing. Doc Ophthalmol 1987, 66:19-33.
• [19]Chan WM, Lam DS, Lai TY, Yuen KS, Liu DT, Chan CK, Chen WQ: Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 2003, 136:836-845.
• [20]Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M: Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Retina 2011, 31:1912-1920.
• [21]Nicoló M, Zoli D, Musolino M, Traverso CE: Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings, in the treatment of central serous chorioretinopathy. Am J Ophthalmol 2012, 153:474-480.
• [22]Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
• [23]van Wijngaarden P, Coster DJ, Williams KA: Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005, 293:1509-1513.
• [24]Weis SM, Cheresh DA: Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437:497-504.
• [25]Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD, Quiroz-Mercado H: A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008, 246:1235-1239.
• [26]Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK: Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009, 223:343-347.
• [27]Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM: Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye (Lond) 2009, 23:488-489.
• [28]Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S: Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009, 19:613-617.
• [29]Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, Schlingemann RO: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 2012, 96:587-590.
• [30]Arias L, Caminal JM, Rubio M, Pujol O, Arruga J: Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 2007, 17:992-995.
• [31]Shimada N, Ohno-Matsui K, Hayashi K, Yoshida T, Tokoro T, Mochizuki M: Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011, 55:378-82.
• [32]Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007, 171:53-67.
• [33]Ford KM, Saint-Geniez M, Walshe T, Zahr A, D'Amore PA: Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 2011, 52:9478-87.
• [34]Eldem B: Visual acuity response of patients with neovascular AMD treated with quarterly dosing of ranibizumab in the EXCITE study. Retina Congress. New York: Scientific Abstracts; 2009.
• [35]Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A: EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011, 118:831-839.
• [36]Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW: Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996, 122:393-403.
• [37]Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT: Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009, 247:767-773.
• [38]Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F: Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001, 20:1403-1413.
• [39]Browning AC, Dua HS, Amoaku WM: The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells. Br J Ophthalmol 2008, 92:1003-1008.
• [40]Aiello LP, Brucker AJ, Chang S, Cunningham ET, D’Amico DJ, Flynn HW, Grillone LR, Hutcherson S, Liebmann JM, O’Brien TP, Scott IU, Spaide RF, Ta C, Trese MT: Evolving guidelines for intravitreous injections. Retina 2004, 24:S3-S19.
• [41]Allain H, Ramelet AA, Polard E, Bentué-Ferrer D: Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004, 27:649-660.
• [42]Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW: CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRECT study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009, 373:1316-1318.
• [43]Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, Cunha-Vaz J, Ambrósio AF: Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010, 59:2637-2645.